Ocular Therapeutix (OCUL)
Market Price (8/23/2026): $11.07 | Market Cap: $2.5 BilSector: Health Care | Industry: Biotechnology
Ocular Therapeutix (OCUL)
Market Price (8/23/2026): $11.07Market Cap: $2.5 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -21% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -1.5% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.49, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -314 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -603% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -8.1%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.2% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 102% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -458%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -490% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -17% Key risksOCUL key risks include [1] its precarious financial position and need for additional capital, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -21% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -1.5% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.49, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -314 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -603% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -8.1%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.2% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 102% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -458%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -490% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -17% |
| Key risksOCUL key risks include [1] its precarious financial position and need for additional capital, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Ocular Therapeutix (OCUL) stock has gained about 20% since 4/30/2026 because of the following key factors:
1. Positive FDA Alignment and Clear Regulatory Path for AXPAXLI.
Ocular Therapeutix announced in May 2026 that it had achieved FDA alignment for the submission of its New Drug Application (NDA) for AXPAXLI (OTX-TKI) in wet Age-related Macular Degeneration (AMD), based on SOL-1 Week 52 efficacy and safety data, along with interim SOL-R safety data. This FDA-aligned path, utilizing the 505(b)(2) regulatory pathway, is projected to accelerate the review timeline by up to 60 days and targets an NDA submission in fiscal Q4 2026. This news significantly de-risked the regulatory outlook for the key pipeline asset.
2. Promising Clinical Data for AXPAXLI.
Further positive Week 52 data from the Phase 3 SOL-1 superiority trial of AXPAXLI for wet AMD, announced in April 2026, demonstrated strong efficacy. A post-hoc analysis of the SOL-1 data estimated up to a 72% reduction in treatment injection burden over 60 weeks with AXPAXLI, compared to a projected on-label aflibercept (2 mg) dosing schedule of every 8 weeks.
Show more
Ocular Therapeutix (OCUL) stock has gained about 20% since 4/30/2026 because of the following key factors:
1. Positive FDA Alignment and Clear Regulatory Path for AXPAXLI.
Ocular Therapeutix announced in May 2026 that it had achieved FDA alignment for the submission of its New Drug Application (NDA) for AXPAXLI (OTX-TKI) in wet Age-related Macular Degeneration (AMD), based on SOL-1 Week 52 efficacy and safety data, along with interim SOL-R safety data. This FDA-aligned path, utilizing the 505(b)(2) regulatory pathway, is projected to accelerate the review timeline by up to 60 days and targets an NDA submission in fiscal Q4 2026. This news significantly de-risked the regulatory outlook for the key pipeline asset.
2. Promising Clinical Data for AXPAXLI.
Further positive Week 52 data from the Phase 3 SOL-1 superiority trial of AXPAXLI for wet AMD, announced in April 2026, demonstrated strong efficacy. A post-hoc analysis of the SOL-1 data estimated up to a 72% reduction in treatment injection burden over 60 weeks with AXPAXLI, compared to a projected on-label aflibercept (2 mg) dosing schedule of every 8 weeks.
3. Fiscal Q2 2026 Earnings Beat and Robust Cash Position.
Ocular Therapeutix reported better-than-expected financial results for fiscal Q2 2026, which ended on June 30, 2026. The company posted a net loss of $0.35 per share, exceeding the consensus analyst estimate of a loss of $0.39 to $0.40 per share. Additionally, revenue reached $13.5 million, modestly surpassing analyst estimates of approximately $13.20 million. The company also reported a strong cash and cash equivalents balance of $598.6 million as of June 30, 2026, providing an expected cash runway into 2028.
4. Favorable Analyst Sentiment and Price Target Upgrades.
Throughout the period, Ocular Therapeutix received positive reinforcement from Wall Street analysts, contributing to a "Moderate Buy" to "Strong Buy" consensus rating and an average price target between $25.75 and $27.09. Notably, during June 2026, HC Wainwright & Co. raised its price target to $25 from $21, and Chardan Capital increased its target to $23 from $21. Several firms reiterated their Buy ratings and high price targets in August 2026, reflecting continued confidence in the company's trajectory.
5. Competitor's Clinical Trial Setback.
In August 2026, rival EyePoint Pharmaceuticals announced that its late-stage trial for DURAVYU, an experimental long-lasting eye implant for wet AMD, missed its primary goal. This development was viewed by analysts as easing the competitive landscape for Ocular Therapeutix's AXPAXLI, contributing to an immediate boost in OCUL's stock price by 6% on August 17, 2026.
Show less
Stock Movement Drivers
Fundamental Drivers
The 18.2% change in OCUL stock from 4/30/2026 to 8/22/2026 was primarily driven by a 19.1% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8222026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.37 | 11.08 | 18.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 52 | 52 | 0.2% |
| P/S Multiple | 40.2 | 47.9 | 19.1% |
| Shares Outstanding (Mil) | 223 | 225 | -0.9% |
| Cumulative Contribution | 18.2% |
Market Drivers
4/30/2026 to 8/22/2026| Return | Correlation | |
|---|---|---|
| OCUL | 18.2% | |
| Market (SPY) | 6.5% | 13.1% |
| Sector (XLV) | 19.6% | 20.0% |
Fundamental Drivers
The 21.2% change in OCUL stock from 1/31/2026 to 8/22/2026 was primarily driven by a 58.9% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8222026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.14 | 11.08 | 21.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 56 | 52 | -6.7% |
| P/S Multiple | 30.1 | 47.9 | 58.9% |
| Shares Outstanding (Mil) | 184 | 225 | -18.2% |
| Cumulative Contribution | 21.2% |
Market Drivers
1/31/2026 to 8/22/2026| Return | Correlation | |
|---|---|---|
| OCUL | 21.2% | |
| Market (SPY) | 11.0% | 26.6% |
| Sector (XLV) | 13.3% | 20.7% |
Fundamental Drivers
The -4.3% change in OCUL stock from 7/31/2025 to 8/22/2026 was primarily driven by a -24.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 8222026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.58 | 11.08 | -4.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 60 | 52 | -12.7% |
| P/S Multiple | 32.9 | 47.9 | 45.6% |
| Shares Outstanding (Mil) | 169 | 225 | -24.7% |
| Cumulative Contribution | -4.3% |
Market Drivers
7/31/2025 to 8/22/2026| Return | Correlation | |
|---|---|---|
| OCUL | -4.3% | |
| Market (SPY) | 22.2% | 17.4% |
| Sector (XLV) | 35.6% | 10.0% |
Fundamental Drivers
The 144.1% change in OCUL stock from 7/31/2023 to 8/22/2026 was primarily driven by a 604.3% change in the company's P/S Multiple.| (LTM values as of) | 7312023 | 8222026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.54 | 11.08 | 144.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 52 | 52 | 0.7% |
| P/S Multiple | 6.8 | 47.9 | 604.3% |
| Shares Outstanding (Mil) | 77 | 225 | -65.6% |
| Cumulative Contribution | 144.1% |
Market Drivers
7/31/2023 to 8/22/2026| Return | Correlation | |
|---|---|---|
| OCUL | 144.1% | |
| Market (SPY) | 73.2% | 29.4% |
| Sector (XLV) | 36.3% | 22.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OCUL Return | -66% | -60% | 59% | 91% | 42% | -9% | -46% |
| Peers Return | -14% | -31% | 94% | 64% | 93% | -27% | 165% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| OCUL Win Rate | 33% | 25% | 42% | 58% | 50% | 38% | |
| Peers Win Rate | 40% | 48% | 45% | 47% | 65% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| OCUL Max Drawdown | -72% | -64% | -73% | -62% | -35% | -43% | |
| Peers Max Drawdown | -55% | -66% | -66% | -59% | -57% | -57% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: EYPT, RGNX, KOD, TARS, ALDX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/21/2026 (YTD)
How Low Can It Go
| Event | OCUL | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -19.7% | -18.8% |
| % Gain to Breakeven | 24.6% | 23.1% |
| Time to Breakeven | 4 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -52.5% | -9.5% |
| % Gain to Breakeven | 110.6% | 10.5% |
| Time to Breakeven | 40 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -12.0% | -6.7% |
| % Gain to Breakeven | 13.7% | 7.1% |
| Time to Breakeven | 6 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -59.0% | -24.5% |
| % Gain to Breakeven | 144.2% | 32.4% |
| Time to Breakeven | 390 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -23.3% | -33.7% |
| % Gain to Breakeven | 30.3% | 50.9% |
| Time to Breakeven | 24 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -43.8% | -19.2% |
| % Gain to Breakeven | 77.8% | 23.8% |
| Time to Breakeven | 433 days | 105 days |
In The Past
Ocular Therapeutix's stock fell -19.7% during the 2025 US Tariff Shock. Such a loss loss requires a 24.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | OCUL | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -52.5% | -9.5% |
| % Gain to Breakeven | 110.6% | 10.5% |
| Time to Breakeven | 40 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -59.0% | -24.5% |
| % Gain to Breakeven | 144.2% | 32.4% |
| Time to Breakeven | 390 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -23.3% | -33.7% |
| % Gain to Breakeven | 30.3% | 50.9% |
| Time to Breakeven | 24 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -43.8% | -19.2% |
| % Gain to Breakeven | 77.8% | 23.8% |
| Time to Breakeven | 433 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -28.6% | -3.7% |
| % Gain to Breakeven | 40.1% | 3.9% |
| Time to Breakeven | 11 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -70.5% | -12.2% |
| % Gain to Breakeven | 239.5% | 13.9% |
| Time to Breakeven | 1779 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -66.8% | -6.8% |
| % Gain to Breakeven | 201.1% | 7.3% |
| Time to Breakeven | 1772 days | 15 days |
In The Past
Ocular Therapeutix's stock fell -19.7% during the 2025 US Tariff Shock. Such a loss loss requires a 24.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Ocular Therapeutix (OCUL)
Ocular Therapeutix, Inc. (OCUL) is a biopharmaceutical company specializing in the formulation, development, and commercialization of therapies for a variety of diseases and conditions affecting the eye. The company's core technology centers around its proprietary bioresorbable hydrogel-based formulation, which enables sustained-release drug delivery for extended therapeutic benefits.
The company currently markets two key products: ReSure Sealant, an ophthalmic device used by surgeons to prevent wound leaks after cataract surgery, and DEXTENZA, a dexamethasone ophthalmic insert for treating post-surgical ocular inflammation and pain, as well as allergic conjunctivitis. Ocular Therapeutix also maintains a robust pipeline, including OTX-TKI, an intravitreal implant in Phase 1 for wet age-related macular degeneration, and OTX-TIC, an intracameral implant in Phase 2 for glaucoma or ocular hypertension. Additionally, they are developing candidates for dry eye disease and have strategic collaborations with Regeneron Pharmaceuticals for retinal diseases and AffaMed Therapeutics for DEXTENZA and OTX-TIC.
Ocular Therapeutix primarily serves the ophthalmic market. Its immediate customers include eye care professionals and surgeons who utilize ReSure Sealant and DEXTENZA in procedures like cataract surgery and for managing ocular inflammation and allergies. The company's pipeline products target patients suffering from chronic and severe eye conditions such as wet age-related macular degeneration, glaucoma, ocular hypertension, and dry eye disease, aiming to provide long-term treatment solutions for these significant patient populations.
AI Analysis | Feedback
Allergan for sustained-release eye treatments.
Regeneron for long-lasting, implantable eye therapies.
AI Analysis | Feedback
- ReSure Sealant: An ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery.
- DEXTENZA: A dexamethasone ophthalmic insert used to treat post-surgical ocular inflammation and pain after ophthalmic surgery, and allergic conjunctivitis.
- OTX-TKI: An axitinib intravitreal implant in Phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases.
- OTX-TIC: A travoprost intracameral implant in Phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.
- OTX-CSI: A cyclosporine intracanalicular insert that has completed Phase 2 clinical trials for the treatment of dry eye disease.
- OTX-DED: A dexamethasone intracanalicular insert in Phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
AI Analysis | Feedback
Ocular Therapeutix (OCUL) sells its products and technologies primarily to other companies and healthcare institutions.
Its major customers include:
- Hospitals and Surgical Centers: These institutions purchase Ocular Therapeutix's marketed products, ReSure Sealant and DEXTENZA, for use in ophthalmic surgeries.
- Ophthalmology Clinics/Practices: These medical practices purchase DEXTENZA for conditions like allergic conjunctivitis and would be the prescribers for Ocular Therapeutix's future ophthalmic products.
- Regeneron Pharmaceuticals, Inc. (symbol: REGN): A strategic collaboration partner that licenses Ocular Therapeutix's sustained-release hydrogel technology for combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases.
- AffaMed Therapeutics Limited: A strategic collaboration partner for the development and commercialization of DEXTENZA and OTX-TIC. AffaMed Therapeutics is a private company and does not have a public symbol.
AI Analysis | Feedback
- Regeneron Pharmaceuticals, Inc. (REGN)
- Mosaic Biosciences
AI Analysis | Feedback
Pravin U. Dugel, MD - President and Chief Executive Officer
Dr. Pravin U. Dugel assumed the roles of President and Chief Executive Officer of Ocular Therapeutix on April 15, 2024, having previously served as Executive Chairman. His prior leadership experience includes serving as President of IVERIC Bio, Inc., Managing Partner at Retinal Consultants of Arizona and the Retinal Research Institute, Clinical Professor at USC Eye Institute, Keck School of Medicine, and a Founding Member of Spectra Eye Institute. Dr. Dugel founded an aviation company that enabled him to travel to Native American reservations to treat patients suffering from preventable blindness. He has consulted for over 50 companies and has held positions on the Boards of Directors for IVERIC Bio and Aerpio Therapeutics. Dr. Dugel is recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials.
Donald Notman - Chief Financial Officer and Chief Operating Officer
Donald Notman has served as Chief Financial Officer of Ocular Therapeutix since September 2017 and was appointed Chief Operating Officer in September 2024. As of January 20, 2026, Mr. Notman is on a temporary medical leave of absence. Before joining Ocular Therapeutix, he was Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc. Mr. Notman also held the position of Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was instrumental in developing the firm's healthcare investment banking capabilities. His career also includes senior-level investment banking roles with Deutsche Banc Alex. Brown and Alex. Brown & Sons.
Jeffrey S. Heier, MD - Chief Scientific Officer
Dr. Jeffrey S. Heier joined Ocular Therapeutix's management team as Chief Scientific Officer in February 2024. He is the Director of the Vitreoretinal Service and Director of Retina Research at Ophthalmic Consultants of Boston (OCB). From 2016 to 2020, Dr. Heier served as co-president & medical director of OCB. He is the Immediate Past President of the Retina Society, a former member of the Executive Committee of the American Society of Retina Specialists, Past President of the New England Ophthalmological Society, and a member of the Macula Society.
Rabia Gurses Ozden, MD - Chief Medical Officer
Dr. Rabia Gurses Ozden continues in her role as Chief Medical Officer, a position she held as of February 2024. She was appointed as Senior Vice President, Clinical Development, in January 2021.
Peter Jarrett, PhD - Chief Technical Officer
Dr. Peter Jarrett assumed the new role of Chief Technical Officer in February 2024. He brings over 40 years of research and development experience, spanning from discovery to commercialization, and joined Ocular Therapeutix in 2007. Previously, he served as Vice President of R&D at Focal, and subsequently as VP of Biomaterials R&D at Genzyme following Genzyme's acquisition of Focal. Dr. Jarrett began his career in Corporate R&D at American Cyanamid and later moved to its Davis and Geck division. His work has focused on developing bioresorbable polymers for medical devices and drug delivery systems, leading to numerous patents and publications.
AI Analysis | Feedback
The key risks for Ocular Therapeutix (OCUL) primarily stem from the inherent challenges of biopharmaceutical development and commercialization in highly competitive ophthalmic markets.
1. Clinical Development, Regulatory Approval, and Market Adoption Risk for AXPAXLI (OTX-TKI)
Ocular Therapeutix faces significant risk related to the successful clinical development, regulatory approval, and subsequent market adoption of AXPAXLI (formerly OTX-TKI), its lead candidate for wet age-related macular degeneration (AMD). Despite recent "positive" Phase 3 SOL-1 trial data, the company's stock experienced a substantial drop, indicating that market expectations for AXPAXLI's durability advantage over existing therapies were not fully met. The company is reportedly pursuing an accelerated regulatory strategy, aiming for approval based on one-year data from a single pivotal trial (SOL-1), which concentrates significant regulatory, clinical, and valuation risk. The FDA's typical guidance for new drug applications in chronic diseases like wet AMD often recommends at least two adequate and well-controlled trials. Furthermore, there are concerns that the observed durability advantage of AXPAXLI in trial settings might diminish in real-world clinical practice, where more stringent retreatment criteria are often applied by retina specialists. Future clinical trial readouts for other programs, such as SOL-R (expected Q1 2027) and HELIOS-3, are anticipated to introduce similar market volatility.
2. Intense Market Competition
The ophthalmic pharmaceutical market is highly competitive, particularly in key therapeutic areas targeted by Ocular Therapeutix's products. The wet AMD market, for instance, is dominated by established blockbuster drugs such as Regeneron's Eylea and Roche's Vabysmo, with Regeneron also having introduced a longer-acting version, Eylea HD. For AXPAXLI to achieve commercial success, it must effectively differentiate itself in this fierce landscape, especially if its durability advantage is not perceived as transformative by the market. Similarly, DEXTENZA, one of the company's marketed products, faces competition from various corticosteroid eye drops. This intense competition necessitates continuous innovation and effective marketing to gain and maintain market share for both current and pipeline products.
3. Commercialization Challenges and Financial Performance
Ocular Therapeutix has demonstrated challenges in effectively commercializing its marketed products, which could impact the future success of its pipeline. The company has reported declining revenue from DEXTENZA, attributed primarily to reimbursement hurdles, despite achieving record annual unit volume. These "commercial execution headwinds" could foreshadow difficulties in penetrating the market with AXPAXLI, even if approved. Financially, the company has experienced widening trailing twelve-month losses and ongoing, sizeable financial losses. While Ocular Therapeutix maintains a robust cash position providing a runway into 2028, sustained losses without significant revenue growth from new product launches pose a long-term financial risk.
AI Analysis | Feedback
AI Analysis | Feedback
ReSure Sealant (Corneal Incisions Following Cataract Surgery)
The global ocular adhesives and sealants market, which includes products like ReSure Sealant used in ophthalmic surgeries, was valued at approximately USD 136.7 million in 2021 and is expected to grow. Annually, around 3 million cataract surgeries are performed in the United States, with over 20 million procedures worldwide. Global cataract surgeries are projected to increase to 50 million by 2050, indicating a substantial addressable market for wound sealants in this area.
DEXTENZA (Post-Surgical Ocular Inflammation and Pain; Allergic Conjunctivitis)
- Post-Surgical Ocular Inflammation and Pain: The global post-operative cataract surgery inflammation treatment market is estimated at USD 5.2 billion in 2025 and is projected to reach USD 10.0 billion by 2035. The global acute ocular pain market, where post-operative eye pain represents a significant application, is projected to grow from USD 2.1 billion in 2024 to USD 3.1 billion by 2030. In 2024, post-operative eye pain constituted approximately USD 0.88 billion of this market.
- Allergic Conjunctivitis: The global allergic conjunctivitis market was valued at USD 3.85 billion in 2023 and is expected to grow to USD 7.61 billion by 2034. Another estimate places the global market at USD 4.8 billion in 2023, projected to reach USD 7.2 billion by 2033. In the United States, an estimated 10 million people annually seek medical attention for allergic conjunctivitis. The U.S. held a significant share of the overall 7MM (United States, EU4, UK, and Japan) allergic conjunctivitis market in 2024.
OTX-TKI (Wet Age-Related Macular Degeneration and Other Retinal Diseases)
- Wet Age-Related Macular Degeneration (wAMD): The global wet age-related macular degeneration market was valued at USD 9.4 billion in 2024 and USD 9,528.8 million across the top 7 markets (US, EU4, UK, and Japan) in 2024. This market is projected to reach USD 18,317.5 million by 2035. The U.S. market alone for wet AMD was approximately USD 2,599 million in 2023.
- Other Retinal Diseases (Overall Retinal Disorder Treatment): The global retinal disorder treatment market was valued at approximately USD 18.3 billion in 2024 and is estimated to grow to USD 34.8 billion by 2034. The U.S. retinal disorder treatment industry was valued at USD 7.1 billion in 2024 and is projected to reach USD 13.1 billion by 2034.
OTX-TIC (Open-Angle Glaucoma or Ocular Hypertension)
- Open-Angle Glaucoma: The global open-angle glaucoma market was valued at USD 5.4 billion in 2024 and USD 7.88 billion in 2023, with projections to reach USD 13.51 billion by 2030. The market across the top 7 markets (US, EU4, UK, and Japan) for open-angle glaucoma reached USD 6.0 billion in 2024 and is expected to reach USD 8.7 billion by 2035.
- Ocular Hypertension: The global ocular hypertension market is estimated to be valued at USD 4.07 billion in 2025, with an expected increase to USD 5.46 billion by 2032. Another report projects the global market to grow from USD 5.1 billion in 2024 to USD 7.2 billion by 2030. The U.S. ocular hypertension market is projected to be USD 1.78 billion in 2024, expanding to USD 2.34 billion by 2030. The United States represents the largest patient pool and market for ocular hypertension treatment.
OTX-CSI and OTX-DED (Dry Eye Disease)
The global dry eye disease market was valued at USD 6.43 billion in 2024 and is projected to grow at a CAGR of 4.04% from 2025 to 2034. Other estimates place the global market size at USD 7.33 billion in 2024, expected to surpass USD 13.26 billion by 2031, or USD 8.00 billion in 2025, growing to USD 15.09 billion by 2034. North America dominated the dry eye syndrome market with a 47.03% share in 2025, and the U.S. market for dry eye syndrome is projected to reach USD 5.60 billion by 2032.
AI Analysis | Feedback
- Launch and Commercialization of AXPAXLI (OTX-TKI) for wet Age-Related Macular Degeneration (AMD): Ocular Therapeutix presented detailed results from its SOL-1 Phase 3 superiority clinical trial for AXPAXLI in wet AMD in late February 2026. The company is optimistic about securing regulatory approval with a single pivotal trial and plans to submit a New Drug Application (NDA) based on the SOL-1 52-week data, potentially leveraging the 505(b)(2) pathway to shorten review times. AXPAXLI, an axitinib intravitreal implant, is anticipated to offer a commercial advantage due to its potential for a superiority label over existing treatments and a less frequent dosing regimen of every 6 to 12 months, which could significantly reduce the burden of care for patients.
- Expansion of AXPAXLI (OTX-TKI) into Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME): Beyond wet AMD, Ocular Therapeutix is actively defining its clinical strategy for AXPAXLI in non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME). The company received positive feedback from the FDA regarding a potential registrational trial design for AXPAXLI in NPDR and is considering a streamlined development approach, potentially advancing with a single Phase 3 HELIOS-3 trial for diabetic retinal disease. This represents an opportunity to tap into a vast and largely untreated diabetic retinopathy market.
- Continued Growth and Market Penetration of DEXTENZA: DEXTENZA, an FDA-approved dexamethasone ophthalmic insert for post-surgical ocular inflammation and pain and allergic conjunctivitis, currently serves as a revenue driver for the company. While 2025 saw a challenging reimbursement environment for DEXTENZA that led to a decrease in total net revenue, the company reported sustained growth in end-user unit sales. Moreover, DEXTENZA net product revenue demonstrated a 26.0% increase in Q2 2025 compared to the previous quarter, indicating a potential stabilization and recovery in sales.
AI Analysis | Feedback
Share Issuance
- In September 2025, Ocular Therapeutix completed an underwritten public offering of 37,909,018 shares at $12.53 per share, generating approximately $475 million in gross proceeds and $445 million in net proceeds.
- The company raised approximately $97 million in gross proceeds in June 2025 through its existing at-the-market (ATM) facility.
- Stockholders approved amendments in June 2025 to increase the number of shares available for issuance under its stock incentive and employee purchase plans by up to 10.75 million additional shares.
Inbound Investments
- Ocular Therapeutix received a $1 million milestone payment in the second quarter of 2023 from AffaMed Therapeutics Limited upon the NMPA's approval of AffaMed's Phase 3 Registrational Study.
- In the second quarter of 2022, the company received a $2 million clinical support payment from AffaMed Therapeutics Limited related to the dosing of the first subject in a Phase 2 clinical trial evaluating PAXTRAVA.
- A $1 million milestone payment was received in the fourth quarter of 2021 following FDA approval of a supplemental New Drug Application (sNDA) for DEXTENZA for allergic conjunctivitis.
Capital Expenditures
- Capital expenditures were reported as $12 million for the full year 2025.
- Capital expenditures were $1.29 million in 2024 and $6.09 million in 2023.
- Proceeds from the September 2025 equity offering are earmarked for infrastructure investments, including manufacturing capital expenditures, to support the development and potential commercialization of AXPAXLI™.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.5% | 83.4% | 124.2% | CAH 390% · MCK 336% · COR 180% |
| Health Care Services | 20 | 20.6% | 45.3% | 9.4% | HIMS 364% · RDNT 152% · DGX 79% |
| Managed Health Care | 8 | 29.7% | -3.2% | 0.4% | OSCR 147% · HQY 66% · ELV 14% |
| Health Care Facilities | 24 | 7.9% | -1.7% | -16.4% | THC 285% · NHC 262% · ENSG 121% |
| Health Care Equipment | 51 | -4.5% | -5.0% | -17.0% | POCI 11300% · UFPT 372% · GKOS 270% |
| Health Care Supplies | 12 | 33.9% | -13.2% | -26.0% | LNTH 288% · HAE 79% · MMSI 29% |
| Pharmaceuticals | 63 | 4.5% | 4.6% | -36.8% | LQDA 2519% · INDV 1253% · ETON 1220% |
| Health Care Technology | 21 | -19.9% | -55.1% | -71.3% | SPOK 108% · HSTM -4% · VEEV -23% |
| Life Sciences Tools & Services | 108 | -2.5% | -28.7% | -71.8% | SNWV 1782% · MEDP 246% · ELMD 241% |
| Biotechnology ← | 365 | 7.8% | -24.9% | -78.0% | BRTX 107550% · CELZ 1771% · DNTH 1536% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| OCUL Falls -13% In 9-Day Spree Amid Pre-Data Silence | 01/07/2026 | |
| Ocular Therapeutix Earnings Notes | 12/28/2026 | |
| Ocular Therapeutix Stock Drop Looks Sharp, But How Deep Can It Go? | 10/17/2025 | |
| Ocular Therapeutix (OCUL) Net Income Comparison | 08/08/2025 | |
| Ocular Therapeutix (OCUL) Debt Comparison | 08/08/2025 | |
| Ocular Therapeutix (OCUL) Revenue Comparison | 08/08/2025 | |
| Ocular Therapeutix (OCUL) Operating Income Comparison | 08/08/2025 | |
| Ocular Therapeutix (OCUL) Operating Cash Flow Comparison | 08/08/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.90 |
| Mkt Cap | 1.5 |
| Rev LTM | 27 |
| Op Inc LTM | -205 |
| FCF LTM | -205 |
| FCF 3Y Avg | -160 |
| CFO LTM | -198 |
| CFO 3Y Avg | -151 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.9% |
| Rev Chg 3Y Avg | 12.5% |
| Rev Chg Q | 34.8% |
| QoQ Delta Rev Chg LTM | 6.7% |
| Op Inc Chg LTM | -9.3% |
| Op Inc Chg 3Y Avg | 6.7% |
| Op Mgn LTM | -348.6% |
| Op Mgn 3Y Avg | -278.3% |
| QoQ Delta Op Mgn LTM | -13.1% |
| CFO/Rev LTM | -299.5% |
| CFO/Rev 3Y Avg | -221.0% |
| FCF/Rev LTM | -316.6% |
| FCF/Rev 3Y Avg | -229.1% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA208742 | DEXTENZA | dexamethasone | insert | 11302018 | -29.9% | -56.5% | -40.1% | 161.6% | 66.4% |
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA208742 | DEXTENZA | dexamethasone | insert | 11302018 | -29.9% | -56.5% | -40.1% | 161.6% | 66.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Developing and commercializing innovative therapies for retinal diseases and other eye conditions | 52 | 64 | 58 | 51 | |
| Collaboration revenue | 0 | ||||
| Product revenue, net | 44 | ||||
| Total | 52 | 64 | 58 | 51 | 44 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Developing and commercializing innovative therapies for retinal diseases and other eye conditions | -266 | -194 | -81 |
| Total | -266 | -194 | -81 |
Price Behavior
| Market Price | $11.08 | |
| Market Cap ($ Bil) | 2.5 | |
| First Trading Date | 07/25/2014 | |
| Distance from 52W High | -31.2% | |
| 50 Days | 200 Days | |
| DMA Price | $9.51 | $9.96 |
| DMA Trend | down | up |
| Distance from DMA | 16.6% | 11.3% |
| 3M | 1YR | |
| Volatility | 56.4% | 71.3% |
| Downside Capture | -52.24 | 103.68 |
| Upside Capture | 91.95 | 69.78 |
| Correlation (SPY) | 11.0% | 17.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.87 | 0.19 | 0.47 | 1.47 | 0.94 | 1.46 |
| Up Beta | 1.48 | 1.06 | 0.91 | 1.99 | 1.77 | 1.66 |
| Down Beta | -0.55 | 0.26 | 0.14 | 0.09 | 0.30 | 1.21 |
| Up Capture | -22% | -36% | 10% | 142% | 46% | 338% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 9 | 20 | 30 | 57 | 112 | 355 |
| Down Capture | 250% | 26% | 88% | 169% | 114% | 108% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 13 | 23 | 32 | 67 | 136 | 385 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OCUL | |
|---|---|---|---|---|
| OCUL | -7.4% | 71.1% | 0.18 | - |
| Sector ETF (XLV) | 28.8% | 16.0% | 1.39 | 10.2% |
| Equity (SPY) | 21.1% | 12.9% | 1.22 | 17.4% |
| Gold (GLD) | 37.5% | 28.8% | 1.10 | 19.4% |
| Commodities (DBC) | 43.2% | 20.2% | 1.66 | -5.6% |
| Real Estate (VNQ) | 12.9% | 13.8% | 0.64 | 5.3% |
| Bitcoin (BTCUSD) | -31.6% | 44.1% | -0.73 | 17.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OCUL | |
|---|---|---|---|---|
| OCUL | 0.3% | 78.6% | 0.35 | - |
| Sector ETF (XLV) | 7.1% | 15.1% | 0.28 | 24.0% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 32.3% |
| Gold (GLD) | 20.6% | 18.6% | 0.90 | 6.4% |
| Commodities (DBC) | 10.4% | 19.6% | 0.41 | 2.0% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 26.1% |
| Bitcoin (BTCUSD) | 10.4% | 52.8% | 0.38 | 22.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OCUL | |
|---|---|---|---|---|
| OCUL | 5.6% | 77.5% | 0.42 | - |
| Sector ETF (XLV) | 10.7% | 16.7% | 0.52 | 27.0% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 30.7% |
| Gold (GLD) | 12.7% | 16.2% | 0.64 | 6.8% |
| Commodities (DBC) | 8.0% | 18.0% | 0.36 | 7.9% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 23.0% |
| Bitcoin (BTCUSD) | 63.1% | 66.1% | 1.03 | 12.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/12/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/3/2026 | 2.8% | 12.5% | |
| 5/5/2026 | -0.6% | -5.0% | -14.5% |
| 2/5/2026 | 4.2% | 7.1% | 20.1% |
| 11/4/2025 | -4.5% | -5.1% | 8.9% |
| 8/5/2025 | -2.8% | 1.7% | 4.8% |
| 5/5/2025 | -12.2% | -19.8% | -5.3% |
| 3/3/2025 | -17.0% | 5.6% | 2.7% |
| 11/14/2024 | -6.4% | -17.2% | -18.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 11 |
| # Negative | 16 | 16 | 15 |
| Median Positive | 4.2% | 5.6% | 16.2% |
| Median Negative | -4.3% | -5.6% | -11.5% |
| Max Positive | 16.4% | 22.1% | 65.7% |
| Max Negative | -17.0% | -22.5% | -21.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/3/2026 | 2.8% | 12.5% | |
| 5/5/2026 | -0.6% | -5.0% | -14.5% |
| 2/5/2026 | 4.2% | 7.1% | 20.1% |
| 11/4/2025 | -4.5% | -5.1% | 8.9% |
| 8/5/2025 | -2.8% | 1.7% | 4.8% |
| 5/5/2025 | -12.2% | -19.8% | -5.3% |
| 3/3/2025 | -17.0% | 5.6% | 2.7% |
| 11/14/2024 | -6.4% | -17.2% | -18.0% |
| 8/7/2024 | 6.1% | 1.4% | 7.0% |
| 5/7/2024 | -3.0% | 2.0% | -12.3% |
| 3/11/2024 | -4.5% | -3.0% | -18.7% |
| 11/7/2023 | -13.2% | -22.5% | 31.0% |
| 8/7/2023 | -10.8% | 2.3% | -10.8% |
| 5/8/2023 | 2.3% | -1.1% | 15.8% |
| 3/6/2023 | 5.3% | -10.0% | -10.2% |
| 1/6/2023 | 16.4% | 22.1% | 34.1% |
| 11/7/2022 | -11.0% | -6.2% | -21.1% |
| 8/8/2022 | -3.0% | 8.7% | 16.2% |
| 5/9/2022 | 1.8% | 3.1% | 19.6% |
| 2/28/2022 | -1.4% | -9.5% | -10.2% |
| 11/8/2021 | 7.5% | -0.3% | -4.6% |
| 8/9/2021 | 2.4% | -3.4% | -0.3% |
| 5/5/2021 | -4.2% | -7.1% | -12.4% |
| 3/11/2021 | 2.6% | -3.0% | -20.2% |
| 1/11/2021 | -1.7% | -7.1% | -11.5% |
| 11/5/2020 | 7.0% | 9.7% | 65.7% |
| 8/7/2020 | -3.0% | -4.7% | -8.7% |
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 11 |
| # Negative | 16 | 16 | 15 |
| Median Positive | 4.2% | 5.6% | 16.2% |
| Median Negative | -4.3% | -5.6% | -11.5% |
| Max Positive | 16.4% | 22.1% | 65.7% |
| Max Negative | -17.0% | -22.5% | -21.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/03/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/05/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 03/03/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/11/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/03/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/05/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 03/03/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/11/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 03/06/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
| 09/30/2021 | 11/08/2021 | 10-Q |
| 06/30/2021 | 08/09/2021 | 10-Q |
| 03/31/2021 | 05/05/2021 | 10-Q |
| 12/31/2020 | 03/11/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/07/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 03/12/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
Recent Forward Guidance
Updated 8/4/2026Latest: Q2 2026 Earnings Reported 8/3/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Injection Burden Reduction | 0.56 | ||||||
Prior: Q3 2025 Earnings Reported 11/4/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2028 Cash Runway | |||||||
Insider Activity
Updated 6/18/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Waheed, Nadia | Chief Medical Officer | Direct | Sell | 6052026 | 8.27 | 14,828 | 122,628 | 2,481,653 | Form |
| 2 | Dugel, Pravin | See Remarks | Direct | Sell | 5282026 | 8.20 | 21,156 | 173,479 | 21,296,794 | Form |
| 3 | Kaiser, Peter | Chief Development Officer | Direct | Sell | 5282026 | 8.20 | 2,967 | 24,329 | 2,182,356 | Form |
| 4 | Heier, Jeffrey S | Chief Scientific Officer | Direct | Sell | 5282026 | 8.20 | 3,018 | 24,748 | 2,626,870 | Form |
| 5 | Nayak, Sanjay | Chief Strategy Officer | Direct | Sell | 5282026 | 8.20 | 1,858 | 15,236 | 2,696,119 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Waheed, Nadia | Chief Medical Officer | Direct | Sell | 6052026 | 8.27 | 14,828 | 122,628 | 2,481,653 | Form |
| 2 | Dugel, Pravin | See Remarks | Direct | Sell | 5282026 | 8.20 | 21,156 | 173,479 | 21,296,794 | Form |
| 3 | Kaiser, Peter | Chief Development Officer | Direct | Sell | 5282026 | 8.20 | 2,967 | 24,329 | 2,182,356 | Form |
| 4 | Heier, Jeffrey S | Chief Scientific Officer | Direct | Sell | 5282026 | 8.20 | 3,018 | 24,748 | 2,626,870 | Form |
| 5 | Nayak, Sanjay | Chief Strategy Officer | Direct | Sell | 5282026 | 8.20 | 1,858 | 15,236 | 2,696,119 | Form |
| 6 | Dugel, Pravin | See Remarks | Direct | Sell | 2252026 | 8.28 | 20,056 | 166,064 | 24,947,822 | Form |
| 7 | Kaiser, Peter | Chief Development Officer | Direct | Sell | 2252026 | 8.28 | 2,810 | 23,267 | 2,228,214 | Form |
| 8 | Heier, Jeffrey S | Chief Scientific Officer | Direct | Sell | 2252026 | 8.28 | 3,057 | 25,312 | 2,677,487 | Form |
| 9 | Nayak, Sanjay | Chief Strategy Officer | Direct | Sell | 2252026 | 8.28 | 1,759 | 14,565 | 2,737,807 | Form |
| 10 | Waheed, Nadia | Chief Medical Officer | Direct | Sell | 2242026 | 7.74 | 3,510 | 27,167 | 2,437,380 | Form |
| 11 | Lindstrom, Richard L MD | Direct | Buy | 2242026 | 7.66 | 60,229 | 461,354 | 1,891,507 | Form | |
| 12 | Notman, Donald | Chief Operating Officer | Direct | Sell | 2172026 | 9.04 | 11,446 | 103,472 | 3,311,858 | Form |
| 13 | Nayak, Sanjay | Chief Strategy Officer | Direct | Sell | 2172026 | 9.04 | 10,348 | 93,546 | 3,005,004 | Form |
| 14 | Dugel, Pravin | See Remarks | Direct | Sell | 2172026 | 9.04 | 124,882 | 1,128,933 | 27,419,025 | Form |
| 15 | Waheed, Nadia | Chief Medical Officer | Direct | Sell | 2172026 | 9.04 | 7,863 | 71,082 | 2,878,490 | Form |
| 16 | Notman, Donald | Chief Operating Officer | Direct | Sell | 2042026 | 8.54 | 6,035 | 51,539 | 3,226,429 | Form |
| 17 | Notman, Donald | Chief Operating Officer | Direct | Sell | 2042026 | 9.14 | 5,455 | 49,859 | 3,508,270 | Form |
| 18 | Nayak, Sanjay | Chief Strategy Officer | Direct | Sell | 11262025 | 12.04 | 1,878 | 22,611 | 3,345,434 | Form |
| 19 | Dugel, Pravin | See Remarks | Direct | Sell | 11262025 | 12.04 | 19,530 | 235,141 | 38,021,838 | Form |
| 20 | Kaiser, Peter | Chief Development Officer | Direct | Sell | 11262025 | 12.02 | 3,007 | 36,144 | 2,301,025 | Form |
| 21 | Heier, Jeffrey S | Chief Scientific Officer | Direct | Sell | 11262025 | 12.04 | 3,469 | 41,767 | 2,961,118 | Form |
| 22 | Saroj, Namrata | Chief Business Officer | Direct | Sell | 11072025 | 10.74 | 25,865 | 277,790 | 1,870,210 | Form |
| 23 | Anderman, Todd | Chief Legal Officer | Direct | Sell | 10102025 | 12.34 | 11,132 | 137,369 | 1,080,589 | Form |
| 24 | Kaiser, Peter | Chief Development Officer | Direct | Sell | 10062025 | 11.03 | 9,653 | 106,473 | 2,144,673 | Form |
| 25 | Heier, Jeffrey S | Chief Scientific Officer | Direct | Sell | 10062025 | 11.04 | 10,502 | 115,942 | 2,753,475 | Form |
| 26 | Notman, Donald | See Remarks | Direct | Sell | 9042025 | 12.43 | 1,066 | 13,250 | 3,838,471 | Form |
| 27 | Kaiser, Peter | Chief Development Officer | Direct | Sell | 8272025 | 12.04 | 3,011 | 36,252 | 2,457,280 | Form |
| 28 | Nayak, Sanjay | Chief Strategy Officer | Direct | Sell | 8272025 | 12.04 | 1,885 | 22,695 | 3,368,046 | Form |
| 29 | Heier, Jeffrey S | Chief Scientific Officer | Direct | Sell | 8272025 | 12.04 | 3,063 | 36,879 | 3,129,328 | Form |
| 30 | Dugel, Pravin | See Remarks | Direct | Sell | 8272025 | 12.04 | 21,494 | 258,788 | 38,856,018 | Form |
| 31 | Waheed, Nadia | Chief Medical Officer | Direct | Sell | 6032025 | 8.05 | 13,861 | 111,581 | 1,664,780 | Form |
Investor Activity (13F)
Updated Aug 23, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Venrock Adviser, LLC | $87.6 Mil | 3.3% | 33 | ADD +41.4% | 13F |
| Octagon Capital Advisors LP | $26.8 Mil | 3.0% | 29 | ADD +20.7% | 13F |
| Defilade Capital Management, L.P. | $12.6 Mil | 1.8% | 31 | ADD +118.2% | 13F |
| Commodore Capital LP | $21.8 Mil | 1.3% | 36 | New | 13F |
| Avoro Capital Advisors LLC | $104.3 Mil | 1.0% | 30 | ADD +14.3% | 13F |
| TCG Crossover Management, LLC | $14.0 Mil | 0.4% | 49 | TRIM -71.3% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Commodore Capital LP | $21.8 Mil | 1.3% | 36 | New | 13F |
| Defilade Capital Management, L.P. | $12.6 Mil | 1.8% | 31 | ADD +118.2% | 13F |
| Venrock Adviser, LLC | $87.6 Mil | 3.3% | 33 | ADD +41.4% | 13F |
| Octagon Capital Advisors LP | $26.8 Mil | 3.0% | 29 | ADD +20.7% | 13F |
| Avoro Capital Advisors LLC | $104.3 Mil | 1.0% | 30 | ADD +14.3% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | As Of | Filing |
|---|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | $35.6 Mil | 1.0% | 29 | Exited | Dec 31, 2025 | 13F |
| Saturn V Capital Management LP | $18.3 Mil | 3.4% | 20 | Exited | Dec 31, 2025 | 13F |
| Spruce Street Capital LP | $9.5 Mil | 3.1% | 27 | Exited | Dec 31, 2025 | 13F |
| Catalio Capital Management, LP | $8.7 Mil | 1.5% | 45 | Exited | Dec 31, 2025 | 13F |
| Patient Square Capital LP | $5.9 Mil | 1.3% | 28 | Exited | Dec 31, 2025 | 13F |
| TCG Crossover Management, LLC | $14.0 Mil | 0.4% | 49 | TRIM -71.3% | Mar 31, 2026 | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | $104.3 Mil | 1.0% | 30 | ADD +14.3% | 13F |
| Venrock Adviser, LLC | $87.6 Mil | 3.3% | 33 | ADD +41.4% | 13F |
| Octagon Capital Advisors LP | $26.8 Mil | 3.0% | 29 | ADD +20.7% | 13F |
| Commodore Capital LP | $21.8 Mil | 1.3% | 36 | New | 13F |
| TCG Crossover Management, LLC | $14.0 Mil | 0.4% | 49 | TRIM -71.3% | 13F |
| Defilade Capital Management, L.P. | $12.6 Mil | 1.8% | 31 | ADD +118.2% | 13F |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.